Net Income: $8.3M (+80.4%); Non-GAAP Net Income: $19.8M (+23.8%); EPS: $0.20 (+81.8%); Non-GAAP EPS: $0.47 (+23.7%); Quick Assets: $383.5M (+23.2%).
2019 Guidance: EXPAREL net product sales: $400M - 410M.
The consensus Revenue and non-GAAP EPS estimate was $93.71M and $0.27, respectively.
Shares are up 2% premarket.
Previously: Pacira Pharmaceuticals beats by $0.20, beats on revenue (Feb. 28)
Now read: Antares Pharma +2% on Q4 results »
Subscribe for full text news in your inbox